Can IVF Costs Be Reimbursed in China? Detailed Explanation of Provincial Medical Insurance Reimbursement Policies in 2025

Opening: Real clinical scenario (doctor's perspective)

Module A: Direct Answer to the Question

I. Direct Answer: Partial Reimbursement is Possible, But with Clear Boundaries

As of 2025, more than ten provinces in China have included some assisted reproductive technology items in the medical insurance reimbursement scope. However, "can be reimbursed" does not mean "full reimbursement," and certainly not "the same for everyone."

• Items that can be reimbursed: Core laboratory operations such as egg retrieval, embryo culture, embryo transfer, intracytoplasmic sperm injection (ICSI), sperm selection, assisted embryo hatching, freeze-thaw embryo recovery, and some related examinations.
• Items that cannot be reimbursed or have limited reimbursement: Imported ovulation induction drugs (e.g., Gonal-f, Puregon), some genetic tests, costs related to third-party assisted reproduction, and non-medical embryo selection.
• Reimbursement ratio: Generally between 50% and 70% across regions, with an annual limit (mostly 10,000 to 30,000 yuan per year in most provinces).
• Prerequisites: Must be a medical insurance participant (employee or resident insurance), meet the medical indications for assisted reproduction, and receive treatment at a designated medical insurance hospital.

Module B: Why This Question Arises – Policy Evolution Background

II. Why Has IVF Reimbursement Become Possible? Three Key Milestones in Policy Evolution

Many people wonder: Why was IVF not reimbursable in the past, but now it suddenly is? Behind this is the combined effect of medical insurance policies, demographic structure, and social needs.

• July 2023 – Beijing breaks the ice: The Beijing Municipal Medical Insurance Bureau took the lead in including 16 assisted reproductive technology items in the Category A reimbursement scope of medical insurance, including core items such as egg retrieval, embryo culture, and embryo transfer, with a reimbursement ratio of about 70% and an annual limit of 15,000 yuan. This set an example nationwide.
• 2024 – Multiple provinces follow: Guangxi, Gansu, Inner Mongolia, Zhejiang, Anhui, Shandong, Sichuan, Jiangsu, and other regions successively introduced policies to include some assisted reproductive items in medical insurance. There are differences among provinces in item scope, reimbursement ratio, and limits.
• 2025 – Expansion and deepening: More provinces join, and some provinces expand the reimbursement scope from "surgical operation categories" to "some examination categories" and "a small number of drug categories," while simplifying the reimbursement process and achieving direct settlement within the hospital.

Behind the policy changes is the gradual shift in the positioning of assisted reproductive technology from "elective medical care" to "basic medical needs." However, the pressure on medical insurance funds has also led governments to be cautious when opening up, resulting in a "one province, one policy" pattern.

Module C: Doctor's Perspective

III. Doctor's Perspective: The Actual Impact of Reimbursement on Treatment Decisions

As a reproductive specialist, I have observed several significant impacts of reimbursement policies on patients' treatment choices:

• Timing of treatment: Some patients wait for their province's policy to be implemented before starting a cycle to reduce financial burden. However, it is important to note that age is a key factor affecting success rates, and it is not recommended to delay excessively while waiting for policies.
• Treatment plan preference: Within the reimbursement scope, doctors will prioritize drugs and procedures covered by medical insurance. However, if a patient has special conditions (e.g., poor ovarian response, repeated implantation failure), imported drugs or additional techniques may still be recommended, and these costs are out-of-pocket.
• Hospital choice: Only designated medical insurance reproductive centers can provide reimbursement. Some patients transfer from non-designated to designated hospitals, but it is important to note that laboratory standards and clinical experience vary among centers, and "whether it can be reimbursed" should not be the sole criterion for selection.

Module G: Most Easily Overlooked Details

IV. Five Most Easily Overlooked Details

In clinical practice, many patients fail to get reimbursement or receive a lower ratio due to neglecting details. Here are the five most common ones:

1. Different insurance types, different rules: Employee insurance and resident insurance have different reimbursement ratios, deductibles, and annual limits. For example, in some regions, employee insurance reimburses 70%, while resident insurance only reimburses 50%.
2. Reimbursement is limited by the "catalog": Not all assisted reproductive items are in the medical insurance catalog. Some provinces only reimburse "egg retrieval, embryo culture, and transfer," while "blastocyst culture, assisted embryo hatching, sperm freezing," etc., may not be included.
3. Annual limit is "cumulative": If you have already used medical insurance for other medical expenses in the current year, the remaining limit may be insufficient. For example, if the annual limit is 15,000 yuan and you have already reimbursed 5,000 yuan, the maximum for IVF is another 10,000 yuan.
4. List of designated hospitals is updated: The list of designated medical insurance reproductive centers is not permanent and may be adjusted annually. Always confirm through the local medical insurance bureau's official website or the hospital before your visit.
5. Drug reimbursement has "medical insurance indications": Some ovulation induction drugs, although included in medical insurance, are only covered for specific indications (e.g., ovulation disorders). If used for IVF stimulation, they may not be reimbursable.

Module H: Most Common Pitfalls

V. Four Most Common Pitfalls

Pitfall	Specific Manifestation	How to Avoid
Visiting a non-designated hospital	Choosing a reproductive center that is not a medical insurance designated hospital, resulting in all costs being out-of-pocket.	Check the designated list on the "National Medical Insurance Service Platform" or the local medical insurance bureau's official website before your visit.
Ignoring "medical insurance indications"	Using a medical insurance drug but the diagnosis does not meet reimbursement requirements, leading to rejection.	When prescribed, proactively ask the doctor: "What diagnosis is needed for this drug to be covered by insurance?"
Not registering for cross-provincial medical treatment	Insured in Province A but undergoing IVF in Province B without handling cross-provincial medical treatment registration, resulting in a significantly reduced reimbursement ratio or no reimbursement.	Before cross-provincial treatment, be sure to complete cross-provincial medical treatment registration through the "National Medical Insurance Service Platform" app.
Overlooking the "annual limit"	Having already reimbursed other expenses earlier in the year, only to find insufficient limit when undergoing IVF mid-year.	Check your personal medical insurance annual remaining limit in advance and plan your treatment time reasonably.

Module K: Factors Affecting Costs

VI. Five Major Factors Affecting Actual Out-of-Pocket IVF Costs

Even with medical insurance reimbursement, the out-of-pocket costs vary significantly among patients. The main influencing factors are:

• Province of residence: Provinces with higher reimbursement ratios and broader catalog scopes (e.g., Beijing, Zhejiang) have lower out-of-pocket costs; provinces with narrower catalog scopes have higher out-of-pocket ratios.
• Hospital level and nature: Tertiary public reproductive centers generally have higher reimbursement ratios; some private or sino-foreign joint venture institutions may not be medical insurance designated.
• Treatment plan: Conventional IVF costs are relatively lower; additional techniques like ICSI and PGT are more expensive and may not be fully covered.
• Drug choice: Imported ovulation induction drugs (costing about 8,000 to 15,000 yuan per cycle) are basically out-of-pocket; domestic drugs (e.g., Lishenbao, urinary gonadotropins) may be partially reimbursable, but their effectiveness varies by individual.
• Individual needs: Whether assisted hatching, blastocyst culture, or embryo freezing is needed will affect the final out-of-pocket amount.

Module N: Special Situations

VII. Special Situations: Cross-Provincial Medical Insurance, Insurance Type Conversion, Policy Transition

7.1 Cross-Provincial Medical Treatment

• After completing cross-provincial medical treatment registration, treatment at a designated reproductive center in the registered location can be settled according to "insured province policy, treatment province catalog." That is, the reimbursement ratio follows the insured province's standard, and the reimbursement scope follows the treatment province's catalog.
• Note: In some regions, the reimbursement ratio for cross-provincial treatment may be reduced by 10% to 20%, and annual limits may not be shared. It is recommended to call the insured province's medical insurance bureau in advance to confirm.

7.2 Conversion Between Employee and Resident Insurance

• Patients who are switching from employee insurance to resident insurance (or vice versa) should start the treatment cycle only after their insurance status is stable; otherwise, reimbursement interruptions or ratio confusion may occur.
• The annual limit is recalculated based on the converted insurance type, but cumulative limits within the same calendar year are usually not combined.

7.3 Transition for New Policies

• Some provinces' new policies are retroactive to January 1 of the current year. Patients who have already completed treatment out-of-pocket before the policy may apply for supplementary reimbursement. However, the supplementary reimbursement process is complex and requires keeping all invoices and medical records.
• It is recommended to follow official notices from the local medical insurance bureau or consult the hospital's medical insurance office to confirm if there is a supplementary reimbursement window.

Module Q: Frequently Asked Questions

VIII. Frequently Asked Questions (Q&A)

Ending: Risk Reminder + Next Steps Author Identity